FREE WEBINAR: Psychedelics For Psychiatrists - At The Forefront Of A Paradigm Shift For Mental-illness

Don’t miss out - Get your tickets early!

Join this FREE, 75-minute online webinar to gain access to insights and learn about ground-breaking treatments to chronic mental health conditions.

Dr Eli Kotler and Mind Medicine Australia will share a special presentation on Psychedelic-Assisted Therapies for psychiatrists from a trauma-informed perspective. Dr Kotler is a consultant psychiatrist, holds an academic position at Monash University through the Alfred Psychiatry Research Centre, and is the medical director of Malvern Private Hospital, the first addiction hospital in Australia. He is a member of the Australasian Professional Society on Alcohol and other Drugs (APSAD).

Dr Kotler is also one of the 50 students in the first intake of Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies (CPAT) with psychiatrists, psychologists, psychotherapists, GPs, addiction specialists, social workers, occupational therapists and counsellors.

Following the presentation there will be a Q & A Panel with Eli Kotler, Peter Hunt AM, Tania de Jong AM and Dr Tra-ill Dowie. They will answer your questions and discuss next steps with SAS-B pathways for your patients to receive psilocybin and MDMA assisted treatments, the CPAT Course and other support offered, and next steps forward for Australia in this exciting field.

WEBINAR SESSION

Date: Tuesday 11 May 2021
Time: 6:55pm for 7:00pm start – 8:15pm (incl Q&A) (AEST)

The presentation WILL BEGIN AT 7:00pm.

Location: Online. A link will be emailed to you with the viewing details.

Support these events:

Whilst our webinars are free of charge, we strongly encourage you to make a donation and support our important mission of making these therapies available through our medical system. This can be done at the time of reserving your ticket. Please share these events with your networks.

More about Mind Medicine Australia and medicinal psychedelic-assisted therapy:

Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients.

Unlike current treatments such as anti-depressants, which only manage the illness and can have nasty side effects, psilocybin and MDMA assisted therapies have been scientifically proven to be a safe and effective cure for anxiety, depression, end-of-life stress, addictions and PTSD after just a short treatment program. These medicines are also currently being researched for dementia, eating disorders, OCD and a number of other conditions. Both medicines have been granted Breakthrough Therapy Status by the FDA in the USA to fast-track their approval. This designation is only given to medicines which may prove to be vastly superior to existing treatments.

At Mind Medicine Australia we are dedicated to helping the now global movement to spread this awareness and ensure these medicines are available via the medical system. Please watch and share our 2 minute animation to find out why psychedelic-assisted psychotherapy needs to be available to those who are suffering.

More about the presenters

Dr Eli Kotler (Moderator)
MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA
Board Member of Mind Medicine Australia
Psychiatrist and Director of Medicine at Malvern Private Hospital

Eli is a consultant psychiatrist, holds an academic position at Monash University through the Alfred Psychiatry Research Centre, and is the medical director of Malvern Private Hospital, the first addiction hospital in Australia. He is a member of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Clinically, Eli is interested in the deep connections between trauma and addiction and works within a neuro-psychoanalytic framework. Eli has overseen the development of a clinical program for addictions focused on trauma, particularly developmental trauma. This has led to an interest in medication-assisted trauma therapy. Eli worked for many years researching neurodegenerative diseases and was the principle investigator on numerous trials for novel therapeutics. He is now involved in addiction research involving the retraining of neural pathways underlying incentive salience in methamphetamine addiction. Through involvement with Monash University, Eli overseas the addiction rotation for medical students.

Dr Tra-ill Dowie
Ph. D
Head of the Faculty of Psychotherapy at Ikon Institute Australia and CPAT Facilitator, Mind Medicine Australia

Dr Tra-ill Dowie is the Head of the Faculty of Psychotherapy at Ikon Institute Australia. Dr Dowie is the Chair of the Australian Counselling Association (ACA) Panel for Trauma Standards & Practice. Dr Dowie is a practising psychotherapist, supervisor and public speaker.

Dr Dowie’s academic life and public lectures cover a broad range of interdisciplinary topics that relate to the human condition: psychiatry, psychotherapy, trauma, continental philosophy, philosophy of mind, anthropology, health and wellbeing, and human optimisation.

He holds dual PhDs, receiving a PhD in Psychiatry from Monash University and a
PhD in Philosophy from the University of Melbourne.

Peter Hunt AM  
B.Com, LL.B  
Founder & Chair of Mind Medicine Australia  

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

Tania de Jong AM  
LL.B (Hons), GradDipMus  
Founder & Deputy Chair of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.  

Please click here to make a tax-deductible donation. 

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.